Form 4: Director Giraudo Boosts PTGX Stake with New Equity Grants

Protagonist Therapeutics Director Bryan Giraudo received grants of restricted stock units and stock options, increasing his beneficial ownership.

Summary

• Bryan Giraudo, a Director at Protagonist Therapeutics, Inc. (PTGX), acquired 2,695 shares of common stock through a grant of restricted stock units (RSUs) on January 2, 2026.
• These RSUs will vest in full on January 15, 2027, contingent on Giraudo's continued service to the company.
• Giraudo also acquired 3,762 stock options with an exercise price of $87.18 per share on January 2, 2026.
• The stock options will vest in 12 equal monthly installments following January 2, 2026, also subject to his continued service.
• Following these transactions, Giraudo directly beneficially owns 17,825 shares of common stock and 3,762 stock options.
• Additionally, 8,000 shares of common stock are indirectly beneficially owned by the Bryan & Courtney Giraudo Trust.

Sentiment

Score: 7

Explanation: The filing reflects a standard, positive event of director compensation through equity grants, which aligns interests. It does not contain any negative or unexpected information, contributing to a moderately positive sentiment.

Positives

• The grants of restricted stock units and stock options align the director's financial interests with those of shareholders, incentivizing long-term performance.
• Increased beneficial ownership by a director can signal confidence in the company's future prospects.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Bryan Giraudo's continued service to Protagonist Therapeutics, Inc., meaning the benefits are not guaranteed if his service ceases.

Future Outlook

The equity grants, with their vesting schedules extending into 2027 and 2036, indicate an expectation of continued service from Director Bryan Giraudo and a long-term alignment of his interests with the company's performance.

Industry Context

Equity grants, including restricted stock units and stock options, are a standard component of compensation packages for directors and executives in publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, to attract and retain talent and align their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Continued service of Bryan Giraudo to Protagonist Therapeutics, Inc. to meet vesting conditions for RSUs and stock options.
• Vesting of stock options in 12 equal monthly installments following January 2, 2026.
• Full vesting of restricted stock units on January 15, 2027.

Key Dates

Recommendation

This Form 4 details routine equity compensation for a director, which is a positive signal for aligning management incentives with shareholder interests. However, it does not introduce new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change from a 'hold' position based solely on this filing. It reinforces a stable governance and compensation structure.

Keywords

Protagonist Therapeutics, PTGX, Form 4, insider transaction, equity grant, restricted stock units, stock options, director compensation